We studied the effects of hibarimicins and hibarimicin-related compounds produced by Microbispora rosea subsp. hibaria [glycosides (hibarimicins A, B, C, D, E, G, H and I) and aglycon (hibarimicinone)] or compounds produced by its mutants [glycosides (HMP-P4 and -Y6), aglycons (HMP-P1 and -Y1) and shunt products (HMP-M1, M2, M3 and -M4)] on v-Src tyrosine kinase and growth and differentiation of human myeloid leukemia HL-60 cells. Among them, hibarimicin B was a strong and the most selective v-Src kinase inhibitor with differentiation inducing activity of HL-60 cells. Hibarimicin E similarly induced HL-60 cell differentiation but had no v-Src kinase inhibitory activity. Hibarimicinone was the most potent v-Src kinase inhibitor, although less selective, and did not induce differentiation of HL-60 cells. Hibarimicin B competitively inhibited ATP binding to the v-Src kinase, but hibarimicinone showed noncompetitive inhibition. These two compounds, however, showed similar mixed types of inhibition against a Src substrate binding to the v-Src kinase. Altogether, these results suggest that signaling molecules other than Src might be more important in the differentiation induction of HL-60 cells.
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Src Substrate Peptide Phosphorylation Assay
The v-Src protein was immunoprecipitated as described were preincubated at room temperature for 30 minutes. In ATP competition experiments, ATP concentration was experiments, the Src substrate peptide concentration was were washed four times with 75mM phosphoric acid (250ml each for 10 minutes) and once with 99.5% EtOH (200ml for 5 minutes). They were then dried and the radioactivity was counted by Cerenkov counting.
Assay of Cell Growth and Differentiation of Leukemia Cells
Human myeloid leukemia HL-60 cells were cultured in suspension in RPMI 1640 medium supplemented with 10% fetal bovine serum. Cell numbers were counted with a Model Zl Counter (Beckman-Coulter Electronics, Miami, FL, USA) after culture for 6 days. Granulocyte differentiation was colorimetrically measured by nitroblue tetrazolium (NBT) reduction as described in the previous report9).
Results and Discussion
In a multiple protein kinase assay using the postnuclear fraction of v-src transformed NIH3T3 cells, not only hibarimicin A and B but also each of the corresponding aglycons, HMP-P1 and hibarimicinone, potently inhibited the Src protein tyrosine kinase (PTK) activity. The assay results of hibarimicins and hibarimicin-related compounds are summarized on Table 1 . Hbbarimicin B was stronger than hibarimicin A (Fig. 2) and hibarimicinone was stronger than HMP-P1 (Fig. 3 ) in v-Src kinase inhibitory activity according to the multiple protein kinase assay. When compared to hibarimicin B (MW=1724) at the molar level, hibarimicinone (MW=924) showed similar inhibition to v-Src kinase activity assayed using multiple protein kinase assay (Table 2 ) or a stronger inhibition to autophosphorylation (Fig. 4) and a Src substrate peptide, p34cdc2 [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] , phosphorylation by immunoprecipitated v-Src kinase (data not shown). Hibarimicinone showed 1.3-or 5.5-fold stronger inhibition against eEF-2K or PKC than hibarimicin B, respectively ( Plotted data were obtained from means of two independent experiments each in duplicate. v-Src kinase inhibitory action but hibarimicin B does (Table 1) . Genistein, a broad-spectrum kinase inhibitor, induced granulocyte differentiation of HL-60 cells10). In conclusion, hibarimicinone was the most potent v-Src kinase inhibitor but was less selective than hibarimicin B and hibarimicin B was a strong and most selective v-Src kinase inhibitor with differentiation inducing activity of HL-60 cells. Hibarimicin E induced HL-60 cell differentiation but had no v-Src kinase inhibitory activity. These results suggest that the differentiation-inducing activity of hibarimicins is not directly associated with Src kinase-inhibiting activity, and may be associated with the modulation of other signaling pathway(s). 
